Bonn\/ Luxem\u00adbourg \u2014 ECBF invests in its 8th port\u00adfo\u00adlio company Biosyn\u00adtia ApS from Denmark. Biosyn\u00adtia is a precis\u00adion fermen\u00adta\u00adtion company focu\u00adsed on repla\u00adcing a fossil-based produc\u00adtion process with a bio-based process for products such as vitamins and other ingre\u00addi\u00adents. ECBF joins Novo Seeds and Sofin\u00adnova Part\u00adners in the share\u00adhol\u00adder struc\u00adture and leads the current round of 11.5 million euros<\/p>\n
Biosyn\u00adtia has closed its EUR 11.5 million Series B round. The indus\u00adtrial biotech company provi\u00addes ingre\u00addi\u00adents from nature on a large scale in a cost-effec\u00adtive and sustainable manner. Using advan\u00adced biotech\u00adno\u00adlogy and proprie\u00adtary R&D tools and know\u00adledge, the company is deve\u00adlo\u00adping unique precis\u00adion fermen\u00adta\u00adtion proces\u00adses to replace fossil alter\u00adna\u00adti\u00adves. The company\u2019s vision is to deve\u00adlop a natu\u00adral and envi\u00adron\u00admen\u00adtally friendly produc\u00adtion process for essen\u00adtial nutri\u00adtio\u00adnal active ingre\u00addi\u00adents that redu\u00adces the use of petro\u00adche\u00admi\u00adcal proces\u00adses and has a posi\u00adtive impact on the envi\u00adron\u00adment. Today, the company has seve\u00adral commer\u00adcial part\u00adner\u00adships, inclu\u00adding colla\u00adbo\u00adra\u00adti\u00adons with major market play\u00aders such as Givau\u00addan and WACKER.<\/p>\n
The Euro\u00adpean Circu\u00adlar Bioe\u00adco\u00adnomy Fund supports Biosyntia The \u20ac11.5 million finan\u00adcing round was secu\u00adred through the invest\u00adment of ECBF and the two exis\u00adting inves\u00adtors Sofin\u00adnova Part\u00adners <\/strong>and Novo Seeds<\/strong>, the early-stage invest\u00adment and start-up team of Novo Holdings A\/S.<\/p>\n Finan\u00adcing enables expan\u00adsion of product range and start of production \u201cOur team is really proud of the reco\u00adgni\u00adtion this invest\u00adment brings. The invest\u00adment enables us to finally offer our custo\u00admers the first and only natu\u00adral as well as sustainable alter\u00adna\u00adtive to the nutri\u00adtio\u00adnal active ingre\u00addi\u00adents available to them today,\u201d says Martin Plam\u00adbech, CEO of Biosyn\u00adtia, and conti\u00adnues: \u201cWith ECBF joining inves\u00adtors Sofin\u00adnova Part\u00adners and Novo Seeds, we are impro\u00adving an alre\u00adady strong inves\u00adtor base. Combi\u00adned with our promi\u00adsing ingre\u00addi\u00adent port\u00adfo\u00adlio, we are poised to create a new global fermen\u00adta\u00adtion-based ingre\u00addi\u00adent manu\u00adfac\u00adtu\u00adrer that can chall\u00adenge today\u2019s incumbents.\u201d<\/p>\n \u201cWe are very exci\u00adted to streng\u00adthen ECBF\u2019s indus\u00adtrial biotech\u00adno\u00adlogy port\u00adfo\u00adlio by part\u00adne\u00adring with Biosyn\u00adtia and its current inves\u00adtors to create a sustainable trans\u00adfor\u00adma\u00adtion that has a very strong commer\u00adcial base. Vitamins and other ingre\u00addi\u00adents should be produ\u00adced from bio-based and not fossil sources, which unfort\u00adu\u00adna\u00adtely is mostly not the case today. Biosyn\u00adtia is in a promi\u00adsing posi\u00adtion to change this, start\u00ading with its B vitamin programs, where the company is alre\u00adady a tech\u00adno\u00adlogy leader,\u201d said Jowita Sewer\u00adska, invest\u00adment direc\u00adtor at ECBF.<\/p>\n About the Euro\u00adpean Circu\u00adlar Bioe\u00adco\u00adnomy Fund (ECBF). About Biosyn\u00adtia Bonn\/ Luxem\u00adbourg \u2014 ECBF invests in its 8th port\u00adfo\u00adlio company Biosyn\u00adtia ApS from Denmark. Biosyn\u00adtia is a precis\u00adion fermen\u00adta\u00adtion company focu\u00adsed on repla\u00adcing a fossil-based produc\u00adtion process with a bio-based process for products such as vitamins and other ingre\u00addi\u00adents. ECBF joins Novo Seeds and Sofin\u00adnova Part\u00adners in the share\u00adhol\u00adder struc\u00adture and leads the current round [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":45473,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1369,1372,1373],"tags":[],"class_list":["post-45469","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investors","category-consultant","category-venture-capital-en"],"yoast_head":"\n
\n<\/strong>
\nEstab\u00adlished in 2020, the ECBF fund (www.ecbf.vc) provi\u00addes finan\u00adcial support to compa\u00adnies deve\u00adlo\u00adping inno\u00adva\u00adtive tech\u00adno\u00adlo\u00adgies, circu\u00adlar busi\u00adness models and sustainable, bio-based products. This includes the indus\u00adtrial BioTech company Biosyn\u00adtia, which produ\u00adces nutri\u00adtio\u00adnal psycho\u00adlogy active ingre\u00addi\u00adents sustain\u00adably and natu\u00adrally. The produc\u00adtion of these active ingre\u00addi\u00adents, such as biotin, has so far been domi\u00adna\u00adted by the use of petro\u00adche\u00admi\u00adcal proces\u00adses. Using biotech\u00adno\u00adlogy and proprie\u00adtary know\u00adledge and tools from rese\u00adarch and deve\u00adlo\u00adp\u00adment, the company deve\u00adlops unique precis\u00adion fermen\u00adta\u00adtion proces\u00adses to replace fossil resources.<\/p>\n
\nBiosyn\u00adtia intends to use the Series B finan\u00adcing to expand its product range on the one hand and to start the produc\u00adtion phase of sustain\u00adably produ\u00adced nutri\u00adtio\u00adnal active ingre\u00addi\u00adents on the other. The first product to be commer\u00adcia\u00adli\u00adzed is a bio-based biotin (vitamin B7) that can be used in dietary supple\u00adments, food and beauty products.<\/p>\n
\n<\/strong>
\nThe Euro\u00adpean Circu\u00adlar Bioe\u00adco\u00adnomy Fund (ECBF) (www.ecbf.vc) invests growth capi\u00adtal in ambi\u00adtious and visio\u00adnary entre\u00adpre\u00adneurs and encou\u00adra\u00adges private and public inves\u00adtors to support the deve\u00adlo\u00adp\u00adment of late-stage bioe\u00adco\u00adnomy compa\u00adnies. The fund aims to make sustainable invest\u00adments in our future and acce\u00adle\u00adrate the tran\u00adsi\u00adtion from a fossil-based to a circu\u00adlar, bio-based economy. The ECBF, which is based in Bonn and has a total fund volume of EUR 300 million, to which the Euro\u00adpean Invest\u00adment Bank (EIB) has contri\u00adbu\u00adted EUR 100 million, will be an important finan\u00adcial instru\u00adment for achie\u00adving the goals of the Euro\u00adpean Green Deal, inclu\u00adding making Europe climate neutral by 2050.<\/p>\n
\n<\/strong>
\nBiosyn\u00adtia (www.biosyntia.com) is an indus\u00adtrial biotech company that deve\u00adlops bioba\u00adsed manu\u00adfac\u00adtu\u00adring proces\u00adses and brings all mission-criti\u00adcal capa\u00adbi\u00adli\u00adties in-house \u2014 from micro\u00adbial deve\u00adlo\u00adp\u00adment to fermen\u00adta\u00adtion opti\u00admiza\u00adtion, product puri\u00adfi\u00adca\u00adtion, formu\u00adla\u00adtion and distri\u00adbu\u00adtion. The company today consists of 20 scien\u00adtists and busi\u00adness deve\u00adlo\u00adpers working from Biosyn\u00adtia\u2019s labo\u00adra\u00adtory and offices in Copen\u00adha\u00adgen, Denmark.
\nBiosyn\u00adtia focu\u00adses prima\u00adrily on deve\u00adlo\u00adping more natu\u00adral and sustainable proces\u00adses for active ingre\u00addi\u00adents used in the beauty and nutri\u00adtion indus\u00adtries, such as vitamins, anti\u00adoxi\u00addants and simi\u00adlar ingre\u00addi\u00adents. The company has deve\u00adlo\u00adped proprie\u00adtary tech\u00adno\u00adlo\u00adgies such as Biosyn\u00adthe\u00adtic Selec\u00adtions\u2122 that drama\u00adti\u00adcally reduce the risk, cost and time requi\u00adred to deve\u00adlop fermen\u00adta\u00adtion proces\u00adses. The company has recei\u00adved more than 15 reco\u00adgni\u00adtion awards, inclu\u00adding one of the most inno\u00adva\u00adtive SMEs in Europe.<\/p>\n","protected":false},"excerpt":{"rendered":"